UNSPSC 51351506: Haloprogesterone

This classification denotes a therapeutic progestin with the molecular formula C21H28BrFO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 803BIX5JG5, chemically known as 17-bromo-6alpha-fluoropregn-4-ene-3,20-dione but generally known as haloprogesterone, which bears US NIH Compound Identifier 19056. European Medicines Agency schedules Haloprogesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08007MIG.

UNSPSC 51351506 Haloprogesterone is a Commodity code under which state and local governments procure branded and generic pharmaceutical products, including hormone therapies and related medications, through cooperative purchasing agreements and direct supply contracts. The scope of work encompasses manufacturer supply of finished pharmaceuticals with complete product documentation, National Drug Codes, packaging specifications, and compliance certifications. Issuing bodies soliciting under this code include state procurement offices administering multistate cooperative purchasing alliances and participating state and local government facilities; the recent activity reflects procurement through cooperative vehicles rather than individual jurisdictional RFPs.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with a response deadline of March 26, 2026. The solicitation requires vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with award contracts effective July 1, 2026 and a two-year term for new vendors. Evaluation heavily favors price competitiveness (75 percent) alongside fixed pricing, EDI capability, administrative fee compliance, and data format adherence. Vendors must maintain $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability coverage, certify cGMP and Drug Supply Chain Security Act compliance, and maintain relationships with at least two of the three wholesalers with chargeback systems.